Abstract
Candida albicans is an opportunistic pathogenic fungus capable of causing infections in an expanding population of immunosuppressed patients. The implementation of proteomics in the post-genomic era of this organism can provide vital information about its biological complexity and pathogenic traits. C. albicans proteomic analyses to date have focused on the understanding of the cell wall, virulence, dimorphism, antifungal drug effects and resistance, and serological response, among others. This exciting and rapid growing discipline should become an indispensable tool in C. albicans research, particularly to address problems that cannot be solved by genomic studies. Furthermore, in the near future it is expected that results from proteomic experiments will lead to novel techniques for the management of candidiasis.
Keywords: Candida albicans, two-dimensional electrophoresis, proteomics, serology, cell wall, immunoproteomics, adhesins, morphogenesis, antifungal resistance
Infectious Disorders - Drug Targets
Title: Proteomics to Study Candida albicans Biology and Pathogenicity
Volume: 6 Issue: 4
Author(s): Derek P. Thomas, Aida Pitarch, Lucia Monteoliva, Concha Gil and Jose L. Lopez-Ribot
Affiliation:
Keywords: Candida albicans, two-dimensional electrophoresis, proteomics, serology, cell wall, immunoproteomics, adhesins, morphogenesis, antifungal resistance
Abstract: Candida albicans is an opportunistic pathogenic fungus capable of causing infections in an expanding population of immunosuppressed patients. The implementation of proteomics in the post-genomic era of this organism can provide vital information about its biological complexity and pathogenic traits. C. albicans proteomic analyses to date have focused on the understanding of the cell wall, virulence, dimorphism, antifungal drug effects and resistance, and serological response, among others. This exciting and rapid growing discipline should become an indispensable tool in C. albicans research, particularly to address problems that cannot be solved by genomic studies. Furthermore, in the near future it is expected that results from proteomic experiments will lead to novel techniques for the management of candidiasis.
Export Options
About this article
Cite this article as:
Thomas P. Derek, Pitarch Aida, Monteoliva Lucia, Gil Concha and Lopez-Ribot L. Jose, Proteomics to Study Candida albicans Biology and Pathogenicity, Infectious Disorders - Drug Targets 2006; 6 (4) . https://dx.doi.org/10.2174/187152606779025815
DOI https://dx.doi.org/10.2174/187152606779025815 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Reduced-Intensity Stem Cell Transplantation for Hematological Malignancies: Current Status and the Future
Current Stem Cell Research & Therapy Paclitaxel Loaded Nanoliposomes in Thermosensitive Hydrogel: A Dual Approach for Sustained and Localized Delivery
Anti-Cancer Agents in Medicinal Chemistry Haploidentical Stem Cell Transplantation in Childhood
Current Cancer Therapy Reviews Transport of Nucleoside Analogs Across the Plasma Membrane: A Clue to Understanding Drug-Induced Cytotoxicity
Current Drug Metabolism Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry Fluoroquinolones in Pediatrics
Current Drug Therapy Dual Receptor-Specific Peptides Modified Liposomes as VEGF siRNA Vector for Tumor-Targeting Therapy
Current Gene Therapy JAK Inhibitors: Pharmacology and Clinical Activity in Chronic Myeloprolipherative Neoplasms
Current Medicinal Chemistry Clinical Importance and Potential Use of Small Molecule Inhibitors of Focal Adhesion Kinase
Anti-Cancer Agents in Medicinal Chemistry Aim for the Readers! Bromodomains As New Targets Against Chagas’ Disease
Current Medicinal Chemistry The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine The Recent Progresses on The Improved Therapy of Melanoma by Novel Drug Delivery Systems
Current Drug Targets Stem Cells as a Novel Tool for Drug Screening and Treatment of Degenerative Diseases
Current Pharmaceutical Design Prevention of Immune-mediated Transfusion-related Acute Lung Injury; from Bloodbank to Patient
Current Pharmaceutical Design Epigenetic Lesions in Malignant Melanoma
Current Pharmaceutical Biotechnology Reactive Oxygen Species, Cancer and Anti-Cancer Therapies
Current Chemical Biology The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part III: Specific Management and Surgical Aspects
Current Cardiology Reviews Editorial [Hot Topic: Interferon Alpha2 in the Treatment of Hematological Malignancies. Status and Perspectives (Guest Editor: Hans Carl Hasselbalch)]
Current Drug Targets Namitecan: a Hydrophilic Camptothecin with a Promising Preclinical Profile
Current Medicinal Chemistry Antibody-Drug Conjugate Targets
Current Cancer Drug Targets